Gavrilova S I, Kolykhalov I V, Ponomareva E V, Fedorova Ya B, Selezneva N D
Mental Health Research Centre, Moscow, Russia.
Zh Nevrol Psikhiatr Im S S Korsakova. 2018;118(5):45-53. doi: 10.17116/jnevro20181185145.
To study the efficacy and safety of cereton (choline alfoscerate) in the treatment of elderly patients with amnestic type of mild cognitive impairment (aMCI), which often represents a pre-dementia (symptomatic) stage of Alzheimer's disease (AD).
Fifty patients (40 women and 10 men; mean age 68,8 years) received three-month therapy with cereton in a dose of 1200 mg/day in 3 divided doses. Fifteen patients received the same treatment again within 1 year. Immediate and delayed (7-9 months after treatment) effects of therapy, including those dependent on the ApoE genotype were assessed with a neuropsychological test battery.
Psychometric measures showed a significant improvement after treatment with cereton. ApoE4 allele noncarriers performed better on tests of immediate and delayed reproduction of 10 words. Although, most indicators achieved in the end of therapy course decreased 7-9 months after treatment, the level of patients cognitive functioning remained at a higher level than before treatment. A repeated course of cereton treatment prevents cognitive deficit increasing during the follow-up period (10-12 months).
The drug is well-tolerated and safe and can be recommended for preventive treatment of dementia in patients with high AD risk, in particular in elderly patients with aMCI syndrome.
研究阿法骨化醇胆碱（cereton）治疗遗忘型轻度认知障碍（aMCI）老年患者的疗效和安全性，aMCI通常代表阿尔茨海默病（AD）的痴呆前期（有症状）阶段。
50例患者（40名女性和10名男性；平均年龄68.8岁）接受为期三个月的阿法骨化醇胆碱治疗，剂量为1200毫克/天，分3次服用。15例患者在1年内再次接受相同治疗。采用神经心理测试组评估治疗的即时和延迟（治疗后7 - 9个月）效果，包括那些依赖载脂蛋白E（ApoE）基因型的效果。
心理测量指标显示，使用阿法骨化醇胆碱治疗后有显著改善。ApoE4等位基因非携带者在10个单词的即时和延迟再现测试中表现更好。尽管治疗疗程结束时达到的大多数指标在治疗后7 - 9个月有所下降，但患者的认知功能水平仍高于治疗前。重复使用阿法骨化醇胆碱治疗可防止随访期间（10 - 12个月）认知缺陷增加。
该药物耐受性良好且安全，可推荐用于AD高风险患者，特别是患有aMCI综合征的老年患者的痴呆预防性治疗。
